The HHS hints J&J’s Stelara may be removed from Medicare negotiations list; Eli Lilly says Mounjaro shortages are starting to improve; Astellas releases promising Izervay data for treating geographic atrophy.
BioNTech cancer work takes center stage with 2 deals fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
FDA proposes banning an ingredient in some fruit-flavored drinks; Sarepta Therapeutics’ Duchenne muscular dystrophy gene therapy brings in $69 million in sales; Abbott receives FDA approval for its HPV screening solution.
That’s the headline in a sobering article published by Endpoints News on Oct. 31 as many independents are losing money, thanks to reimbursement rates coming in below acquisition costs, on glucagon-like peptide-1 receptor agonists like Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lily’s Mounjaro. It’s backed up by NCPA’s own recent informal survey of pharmacists, with a whopping 95 percent reporting they were paid an average of $42 below cost to acquire GLP-1s.